ImmuPharma PLC
ImmuPharma PLC (LSE: IMM) is trading at £0.03, about ₹4 at today's GBP/INR rate, as of 25 Sep 2026, 11:35 AM ET, up 2.03% today. Indian residents can buy ImmuPharma from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
£0.03
Today's high
£0.04
52 week low
£0.03
52 week high
£0.15
IMM opened at £0.03, closed previously at £0.03, and has traded between £0.03 and £0.15 over the past 52 weeks.
About
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
Key statistics
Avg. volume
1.81M
Market cap
£20.40M
P/E Ratio
-2.62
Price-to-sales ratio
0.00
Enterprise value
£19.71M
Free cash flow yield
-13.57%
Debt-to-equity ratio
0.00
Return on equity
-559.87%
ROIC
-119.72%
Beta
3.00
Dividend yield
0.00%
Last dividend
£0.00
Financial overview
Revenue
£0.00
Earnings per share
-£0.00
Free cash flow
-£2.37M
Net profit margin
0.00%
Gross margin
0.00%
EBITDA
-£2.51M
Revenue growth
—
Similar securities
This is not an investment recommendation
How to buy ImmuPharma from India
Indian residents can buy ImmuPharma shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to GBP.
Search for ImmuPharma and place an order
Find ImmuPharma by name or by its ticker, IMM, and choose an order type. ImmuPharma trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your ImmuPharma position in GBP and INR. ImmuPharma pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in ImmuPharma from India
Trading and taxes when buying ImmuPharma from India
Trading and limits
- Trading hours
- 8:00 am – 4:30 pm UK
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneImmuPharma does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- Transaction tax
- The UK charges 0.5% Stamp Duty Reserve Tax when buying direct company shares electronically on the LSE; ETFs and UCITS funds do not attract it.
- Estate or inheritance tax
- May applyShares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents.Estate tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy ImmuPharma stock?
Yes. ImmuPharma (IMM) has been listed on the London Stock Exchange since 2003, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to GBP. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one ImmuPharma share cost in rupees?
One ImmuPharma share is £0.03 — about ₹4 at a GBP/INR rate of 126.89 on 27 Sep 2026. Both the ImmuPharma price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying ImmuPharma from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on ImmuPharma shares taxed in India?
Non-residents are exempt from UK capital gains tax on the disposal of listed shares, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the GBP/INR rate on the purchase and the sale date, so the rupee move counts alongside the ImmuPharma price. Paasa issues a capital-gains statement for your return.
Does ImmuPharma pay a dividend?
No. ImmuPharma does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade ImmuPharma from India?
The London Stock Exchange trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when the UK is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on ImmuPharma shares held from India?
Shares in UK-incorporated companies are UK-situs assets and fall within UK Inheritance Tax, charged at 40% above the £325,000 threshold for non-residents. It applies to your overall holdings in that jurisdiction rather than to any one position.
Are there transaction taxes when buying ImmuPharma?
The UK charges 0.5% Stamp Duty Reserve Tax when buying direct company shares electronically on the LSE; ETFs and UCITS funds do not attract it. This is charged by the market, not by Paasa.
Do I have to declare ImmuPharma shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your ImmuPharma holding, its cost and its closing value.
How do I sell ImmuPharma and bring the money back to India?
You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in GBP in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.